Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 7.12% is 299% above its 5-year average of -3.58%, near the high end of its 5-year range (-23.11%–18.56%).
24.81% above its 12-month average of 5.70%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 2.04%.
EBITDA MARGIN
7.12%
EBITDA MARGIN AVG TTM
5.70%
EBITDA MARGIN AVG 3Y
2.23%
EBITDA MARGIN AVG 5Y
-3.58%
EBITDA MARGIN AVG 10Y
-21.76%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.81%
CURRENT VS 3Y AVG
+219.06%
CURRENT VS 5Y AVG
+298.93%
CURRENT VS 10Y AVG
+132.73%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Inspire Medical Systems, Inc.
Market Cap
$2.02B
EBITDA Margin
7.12%
TTM Avg
5.70%
3Y Avg
2.23%
5Y Avg
-3.58%
Market Cap
$1.90B
EBITDA Margin
1.74%
TTM Avg
-0.52%
3Y Avg
3.36%
5Y Avg
2.51%
Market Cap
$2.16B
EBITDA Margin
-755.79%
TTM Avg
-753.93%
3Y Avg
-709.93%
5Y Avg
-1157.85%
Market Cap
$1.74B
EBITDA Margin
16.41%
TTM Avg
1.22%
3Y Avg
-1.65%
5Y Avg
4.31%
Market Cap
$1.71B
EBITDA Margin
-628.14%
TTM Avg
-766.74%
3Y Avg
-948.44%
5Y Avg
-801.32%
Market Cap
$2.52B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$2.76B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$1.00B
EBITDA Margin
3.96%
TTM Avg
-13.21%
3Y Avg
-146.19%
5Y Avg
-104.68%
Market Cap
$474.59M
EBITDA Margin
0.24%
TTM Avg
-1.36%
3Y Avg
-6.49%
5Y Avg
-5.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. (INSP) | $2.02B | 7.12% | 5.70% | 2.23% | -3.58% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.90B | 1.74% | -0.52% | 3.36% | 2.51% |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.16B | -755.79% | -753.93% | -709.93% | -1157.85% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.74B | 16.41% | 1.22% | -1.65% | 4.31% |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.71B | -628.14% | -766.74% | -948.44% | -801.32% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.52B | -270.04% | -444.88% | -365.27% | -89273.54% |
| TransMedics Group, Inc. (TMDX)vs › | $2.76B | 22.42% | 17.70% | -0.76% | -37.34% |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 3.96% | -13.21% | -146.19% | -104.68% |
| NeoGenomics, Inc. (NEO)vs › | $474.59M | 0.24% | -1.36% | -6.49% | -5.53% |
| NRC Health (NRC)vs › | $458.62M | 21.99% | 25.40% | 28.98% | 31.97% |
Gross Margin
86.1%
EBITDA Margin
7.1%
Operating Margin
6.0%
Net Margin
15.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 2.04% |
| 2026-03-31 | 1.95% |
| 2025-12-31 | 18.56% |
| 2025-09-30 | 5.93% |
| 2025-06-30 | 0.05% |
| 2025-03-31 | 0.77% |
| 2024-12-31 | 14.33% |
| 2024-09-30 | 7.96% |
| 2024-06-30 | 3.31% |
| 2024-03-31 | -8.77% |
| 2023-12-31 | 5.25% |
| 2023-09-30 | -8.28% |
| 2023-06-30 | -10.55% |
| 2023-03-31 | -14.78% |
| 2022-12-31 | 0.17% |
| 2022-09-30 | -15.28% |
| 2022-06-30 | -14.87% |
| 2022-03-31 | -22.62% |
| 2021-12-31 | -1.88% |
| 2021-09-30 | -15.34% |
| 2021-06-30 | -23.11% |
| 2021-03-31 | -38.30% |
| 2020-12-31 | -14.80% |
| 2020-09-30 | -27.01% |
| 2020-06-30 | -185.72% |
| 2020-03-31 | -76.14% |
| 2019-12-31 | -33.97% |
| 2019-09-30 | -40.83% |
| 2019-06-30 | -44.75% |
| 2019-03-31 | -53.38% |
| 2018-12-31 | -28.94% |
| 2018-09-30 | -34.85% |
| 2018-06-30 | -50.64% |
| 2018-03-31 | -50.84% |
| 2017-12-31 | -37.51% |
| 2017-09-30 | -49.15% |
| 2017-06-30 | -71.63% |
| 2017-03-31 | -77.04% |
